Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

08. November 2024 16:30 ET | Quelle: Teva Pharmaceutical Industries Ltd

Teva to Present at the Jefferies London Healthcare Conference

TEL AVIV, Israel, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at the...
08. November 2024 16:23 ET | Quelle: Autolus Therapeutics plc

Autolus Therapeutics Announces FDA Approval of AUCATZYL® (obecabtagene autoleucel – obe-cel) for adults with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)

Autolus Therapeutics Announces FDA Approval of AUCATZYL® (obe-cel) for adults with relapsed/refractory B-cell acute lymphoblastic leukemia
08. November 2024 16:01 ET | Quelle: Fate Therapeutics, Inc.

Fate Therapeutics Presents Pan-tumor Targeting Preclinical Data for FT836 MICA/B-targeted CAR T-cell Product Candidate at 2024 SITC Annual Meeting

Multiplexed-engineered, iPSC-derived CAR T Cell Targets Proteins Expressed on Cancer Cells in Response to Cellular Stress and Malignant Transformation Off-the-shelf Product Candidate Incorporates...
08. November 2024 13:30 ET | Quelle: Cue Biopharma, Inc.

Cue Biopharma Presents Positive Updated Data from its Phase 1 Trials of CUE-101 and CUE-102 in Head and Neck Cancer and WT1 Positive Cancers at the SITC 39th Annual Meeting

Objective response rate (ORR) of 46%, 12-month overall survival (OS) of 91.3% and a median overall survival (mOS) of 21.8 months in first line (1L) HPV+ R/M HNSCC patients treated with CUE-101 and...
08. November 2024 10:05 ET | Quelle: Compass Therapeutics

Compass Therapeutics Presents Novel Biomarker Data Related to CTX-471 Clinical Activity at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting

New data showed a correlation between the levels of neural cell adhesion molecule (NCAM or CD56) expression and response and disease control in patients treated with CTX-471 monotherapy.Predictive...
08. November 2024 08:00 ET | Quelle: Vera Therapeutics

Vera Therapeutics to Participate at Upcoming Investor Conferences

BRISBANE, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative...
08. November 2024 07:00 ET | Quelle: Bright Peak Therapeutics, Inc.

Bright Peak Therapeutics Presents New Data at the 2024 Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

-- BPT958, a bifunctional PD-1 immunoconjugate with a masked IL-2 payload designed to be processed specifically in the tumor microenvironment - --In preclinical models, BPT958 induces...
07. November 2024 19:16 ET | Quelle: Extremity Medical

Critical Facts Surrounding the Recent U.S. Patent Trial and Appeal Board Decision in Favor of Extremity Medical Against Petition from Fusion Orthopedics

Extremity Medical’s ‘166 patent is valid, and the patent survives Fusion Orthopedics’ attempt to invalidate it.
07. November 2024 17:09 ET | Quelle: Spherix Global Insights

Spherix Global Insights Focuses on Earlier use of Advanced Treatments in Hidradenitis Suppurativa (HS) as a Catalyst for Better Patient Outcomes

EXTON, PA, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Spherix Global Insights has published a new white paper, Earlier Diagnosis and Treatment: The Key to Better Outcomes in Hidradenitis Suppurativa,...
07. November 2024 16:46 ET | Quelle: Tilray Brands, Inc.

Tilray Medical annonce les résultats positifs d’une étude sur l’extrait de cannabis oral dans le traitement des vomissements induits par la chimiothérapie

SYDNEY, Australie, 07 nov. 2024 (GLOBE NEWSWIRE) -- Tilray Medical, une division de Tilray Brands, Inc., ci-après « Tilray Brands » (NASDAQ : TLRY et TSX : TLRY) et leader mondial du cannabis...

Vorherige Seite

Nächste Seite